SCHEMBL13429381

SCHEMBL13429381

Nc1ccncc1CNc1cccc(Oc2cc(=O)[nH]c3ccccc23)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
KMT2A Q03164 1/20 0.44
AKT1 P31749 1/20 0.38
PTK6 Q13882 2/20 0.37
GRK2 P25098 3/20 0.37
KDM4C Q9H3R0 1/20 0.36
IDH1 O75874 1/20 0.35
MAPT P10636 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
ALDH1A1 P00352 2/20 0.35
ALPG P10696 1/20 0.35
HPGD P15428 1/20 0.35
BRAF P15056 3/20 0.35
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35
GRIN2B Q13224 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13429262 0.84 F2 (0.46) MEN1GAAKMT2APTK6GRK2
SCHEMBL3214616 0.84 VCP (0.45) MEN1GAAKMT2APTK6IDH1
SCHEMBL3214639 0.83 SMN1; SMN2 (0.49) MEN1GAAKMT2APTK6MAPT
SCHEMBL13429368 0.80 MEN1 (0.42) MEN1GAAKMT2APTK6BRAF
SCHEMBL13428972 0.80 GAA (0.44) MEN1GAAKMT2APTK6IDH1
SCHEMBL3222698 0.80 ALDH1A1 (0.43) MEN1GAAKMT2AGRK2ALDH1A1
SCHEMBL13429316 0.80 KMT2A (0.52) MEN1GAAKMT2APTK6IDH1
SCHEMBL3219003 0.80 BRAF (0.48) MEN1GAAKMT2APTK6BRAF
SCHEMBL13429256 0.79 MAOA (0.44) MEN1GAAKMT2APTK6MAPT
SCHEMBL13428997 0.79 MEN1 (0.41) MEN1GAAKMT2AIDH1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA MEN1 2648/4885GAA 1227/4885KMT2A 2445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.